4th Quarter - Report

EISAI INC. for EISAI INC.

Firm
Client
Income
—
Expenses
$340,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Ongoing discussions and updates Helsinn Healthcare SA v Teva Pharmaceuticals USA Inc., Teva Pharmaceutical Industries, Ltd.

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Regulatory and legislative health care issues impacting pricing and access Implementation of Chronic Care Act of 2017 Regulatory and legislative health care issues, including the 340B program Issues related to diagnosis and treatment of obesity Issues related to the diagnosis and treatment of Alzheimer's Disease FDA Guidance on Alzheimer's Disease Drug Development

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 1953/S. 830 - Treat and Reduce Obesity Act of 2017 Revisions to Medicare reimbursement programs to cover obesity products Changes to reimbursement structure of Medicare Part D program Changes to coverage policy for certain drugs in the Medicare Part D program Proposed Part B International Pricing Index Demonstration program

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 830 (115th), H.R. 1953 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.